Biontech Se ADR BNTX

$87.06 +0.20 (0.23%)

Valuation

Market cap
22,282,872,000
Revenue TTM
$3,247,010,000
Net income TTM
$-1,285,380,000
PE ratio
0.00
Forward PE
—
Profit margin
-39.59%
Debt to equity
0.02

Trading

Volume
1,076,700
Avg volume
1,342,180
Day's range
$85.00 – $87.27
Shares out
252,884,000
Stochastic %K
27%
Beta
1.25
Analysts
Strong Sell
Price target
$121.72

Price

Company profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast...

Show more

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Industry
Biotechnology
Sector
Healthcare
Phone
49 6131 9084
Website
https://www.biontech.de
Address
An der Goldgrube 12, Mainz, Germany

Latest news

Stocktwits

SuperGreenToday Oct 27, 5:37 AM
$BNTX Share Price: $86.90 Contract Selected: Feb 19, 2027 $90 Calls Buy Zone: $7.80 – $9.64 Target Zone: $14.07 – $17.20 Potential Upside: 70% ROI Time to Expiration: 115 Days | Updates via https://fxcapta.com/stockinfo/
1 replies
TopPi Oct 26, 3:52 PM
$YNVYF watchlist: $YNVYF short before FDA approval 🎉✅ Shareprice: $0.04 https://www.linkedin.com/posts/sapphirosuk_adlm-sapphiors-adlm-activity-7490309281234272256-Yx6L $MRNA & $NVAX & $BNTX very interesting
0 replies
OpenOutcrier Oct 26, 12:40 PM
$BNTX (-2.9% pre) BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach https://ooc.bz/l/118499
0 replies
IndyOne Oct 26, 11:46 AM
$BNTX Another failure. CEO and CMO leaving makes perfect sense. Their ideas did not work.
1 replies
Sergey_stockdoc Oct 26, 11:44 AM
$BNTX As stated, this will continue dropping with Moderna due to assymetric risk, especially when the pipeline is years out. I reiterate my $80 assumption.
1 replies
filecrux Oct 26, 11:02 AM
$BNTX Follow-up: German drugmaker BioNTech's HER2 drug beat chemo in breast cancer only modestly. 🏢 BioNTech is a Mainz-based cancer drug developer worth about $22.28B at $88.115 a share at 16:00 ET on October 23, 2026, with €7.68B of cash and cash equivalents as of December 31, 2025 📉 The companies say the benefit would be limited in HR+/HER2-low metastatic breast cancer, and lung inflammation (ILD) was more frequent than in earlier trials, with a small share of severe or fatal cases ✅ On the other side, the trial did meet its primary endpoint, and the drug is still in a second Phase 3 trial in HER2-expressing endometrial cancer and a Phase 1/2 solid-tumor trial, among the 13 Phase 3 trials BioNTech says it is running 📅 Next: BioNTech and DualityBio say they will discuss the data and decide next steps; no date given Source: SEC 6-K, Oct 26 + SEC 6-Ks, Oct 13 and Oct 19
0 replies
SoYeonPicks Oct 26, 9:37 AM
$BNTX well that result sucks...
0 replies
Rayvio_News_Filter Oct 26, 9:01 AM
$BNTX 🏥 BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. reported topline Phase 3 DYNASTY-Breast02 results showing trastuzumab pamirtecan met the primary endpoint with a statistically significant but modest progression-free survival improvement versus chemotherapy in chemotherapy-naïve HR+/HER2-low metastatic breast cancer; overall survival data were immature and interstitial lung disease rates were higher. Curated for market relevance
0 replies